{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T05:25:48Z","timestamp":1696742748748},"reference-count":18,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T00:00:00Z","timestamp":1279670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T00:00:00Z","timestamp":1279670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidem. Drug Safe."],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1002\/pds.2008","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T14:14:57Z","timestamp":1279721697000},"page":"876-877","source":"Crossref","is-referenced-by-count":2,"title":["Neuroleptic malignant syndrome: half a century of uncertainty suggests a Chimera"],"prefix":"10.1002","volume":"19","author":[{"given":"P. Ken","family":"Gillman-Retired","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,21]]},"reference":[{"key":"10.1002\/pds.2008-BIB1|cit1","doi-asserted-by":"crossref","DOI":"10.1002\/pds.1937","article-title":"Neuroleptic malignant syndrome and its controversies","author":"Margetic","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1002\/pds.2008-BIB2|cit2","doi-asserted-by":"crossref","DOI":"10.1002\/mds.23220","article-title":"Neuroleptic malignant syndrome: mechanisms, interactions and causality","author":"Gillman","year":"2010","journal-title":"Mov Disord"},{"key":"10.1002\/pds.2008-BIB3|cit3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1192\/bjp.150.6.752","article-title":"The neuroleptic malignant syndrome, so-called. A survey of the world literature","volume":"150","author":"Kellam","year":"1987","journal-title":"Br J Psychiatr"},{"key":"10.1002\/pds.2008-BIB4|cit4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archpsyc.1986.01800090025005","article-title":"Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the \u2018neuroleptic malignant syndrome\u2019","volume":"43","author":"Levinson","year":"1986","journal-title":"Arch Gen Psychiatr"},{"key":"10.1002\/pds.2008-BIB5|cit5","first-page":"295","article-title":"The environment and disease: association or causation","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1002\/pds.2008-BIB6|cit6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00002018-200730040-00006","article-title":"Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance","volume":"30","author":"Perrio","year":"2007","journal-title":"Drug Saf"},{"key":"10.1002\/pds.2008-BIB7|cit7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2044.2006.04588.x","article-title":"Extracting value from case reports: lessons from Serotonin toxicity","volume":"61","author":"Gillman","year":"2006","journal-title":"Anaesthesia"},{"key":"10.1002\/pds.2008-BIB8|cit8","first-page":"817","article-title":"Neuroleptic malignant syndrome without the use of neuroleptics","volume":"145","author":"Heyland","year":"1991","journal-title":"CMAJ"},{"key":"10.1002\/pds.2008-BIB9|cit9","first-page":"790","article-title":"Clomipramine and neuroleptic malignant syndrome: literature on adverse reactions to psychotropic drugs continues to confuse","volume":"330","author":"Isbister","year":"2005","journal-title":"BMJ"},{"key":"10.1002\/pds.2008-BIB10|cit10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.jcp.0000186741.30019.a3","article-title":"Understanding toxidromes: serotonin toxicity. A commentary on Montanes-Rada et al","volume":"25","author":"Gillman","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/pds.2008-BIB11|cit11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1472-8206.1998.tb00976.x","article-title":"Serotonin syndrome: history and risk","volume":"12","author":"Gillman","year":"1998","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1002\/pds.2008-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1176\/appi.ajp.160.7.1233","article-title":"Catatonia in psychiatric classification: a home of its own","volume":"160","author":"Taylor","year":"2003","journal-title":"Am J Psychiatr"},{"key":"10.1002\/pds.2008-BIB13|cit13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/157488609787354387","article-title":"Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics","volume":"4","author":"Odagaki","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1002\/pds.2008-BIB14|cit14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1385\/1-59259-902-8:029","volume-title":"Parkinsonism-Hyperpyrexia Syndrome in Parkinson's Disease, in Movement Disorder Emergencies: Diagnosis and Treatment","author":"Factor","year":"2005"},{"key":"10.1002\/pds.2008-BIB15|cit15","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/mds.1166","article-title":"Neuroleptic malignant syndrome in advanced Parkinson's disease","volume":"16","author":"Gordon","year":"2001","journal-title":"Mov Disord"},{"key":"10.1002\/pds.2008-BIB16|cit16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00005053-198105000-00011","article-title":"Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs","volume":"169","author":"Toru","year":"1981","journal-title":"J Nerv Ment Dis"},{"key":"10.1002\/pds.2008-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1001\/jama.1985.03360190098033","article-title":"A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal","volume":"254","author":"Friedman","year":"1985","journal-title":"JAMA"},{"key":"10.1002\/pds.2008-BIB18|cit18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.comppsych.2006.10.004","article-title":"Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence","volume":"48","author":"Gurrera","year":"2007","journal-title":"Compr Psychiatr"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2008","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pds.2008\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T06:50:45Z","timestamp":1685688645000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2008"}},"subtitle":["LETTER TO THE EDITOR"],"short-title":[],"issued":{"date-parts":[[2010,7,21]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"URL":"https:\/\/doi.org\/10.1002\/pds.2008","archive":["Portico"],"relation":{},"ISSN":["1053-8569"],"issn-type":[{"value":"1053-8569","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7,21]]}}}